Safety and Efficacy of Inhaled XW001 For Hospitalized COVID-19 Patients Requiring Oxygen Therapy
Status:
Not yet recruiting
Trial end date:
2022-04-10
Target enrollment:
Participant gender:
Summary
This is a multiregional, randomized, double-blind, placebo-controlled Phase 2 study in
patients with confirmed symptomatic COVID-19, designed to evaluate the safety, tolerability,
efficacy, and PK of XW001 (IL-29 analog) inhalation solution. The purpose of this study is to
evaluate whether treatment with XW001 reduces the likelihood of worsening disease in patients
with severe COVID-19. Hospitalized patients on oxygen therapy by mask or nasal prongs
(WHO-OSCI score 4) will be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Sciwind Biosciences APAC CO Pty. Ltd.
Collaborators:
Hangzhou Sciwind Biosciences Co., Ltd. Sciwind Biosciences USA Co., Ltd